Pharmacokinetic mismatch does not lead to emergence of isoniazidor rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: A new paradigm for antituberculosis drug scheduling

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5085-5089

  Srivastava, Shashikant ^a   Sherman, Carleton ^a   Meek, Claudia ^b   Leff, Richard ^b   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; HOLLOW FIBER; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 80054715588     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00269-11     Document Type: Article

References (30)

1. Ahmad, Z., et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
2. Anonymous. 1948. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 30:769-782.
3. Bangsberg, D. R., et al. 2006. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20:223-231.
4. Bangsberg, D. R., D. L. Kroetz, and S. G. Deeks. 2007. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr. HIV/AIDS Rep. 4:65-72. (Pubitemid 46806622)
5. Benator, D., et al. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360:528-534.
6. Blumberg, H. M., et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
7. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
8. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis Software. Biomedical Simulations Resource, Los Angeles, CA.
9. East African/British Medical Research Council. 1979. Tuberculosis in Kenya: follow-up of the second 1974 national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey. Tubercle 60:125-149.
10. Gagneux, S. 2009. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 15(Suppl. 1):66-68.
11. Gardner, E. M., W. J. Burman, J. F. Steiner, P. L. Anderson, and D. R. Bangsberg. 2009. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 23:1035-1046.
12. Gumbo, T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 54:1484-1491.
13. Gumbo, T., et al. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. (Pubitemid 350057771)
14. Gumbo, T., et al. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201. (Pubitemid 46080051)
15. Gumbo, T., et al. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51:2329-2336. (Pubitemid 47047307)
16. Gumbo, T., C. S. Siyambalapitiyage Dona, C. Meek, and R. Leff. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
17. McIlleron, H., et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
18. Mitchison, D. A. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15. (Pubitemid 28108937)
19. Mitchison, D. A., A. Jindani, G. R. Davies, and F. Sirgel. 2007. Isoniazid activity is terminated by bacterial persistence. J. Infect. Dis. 195:1871-1872. (Pubitemid 46870262)
20. Oyugi, J. H., et al. 2007. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21:965-971. (Pubitemid 46684328)
21. Pasipanodya, J., and T. Gumbo. 2011. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 55:24-34.
22. Ribaudo, H. J., et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin. Infect. Dis. 42:401-407. (Pubitemid 43122320)
23. Rieder, H. L. 2002. Interventions for tuberculosis control and elimination, p. 15-93. International Union against Tuberculosis and Lung Disease, Paris, France.
24. Selkon, J. B., et al. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. World Health Organ. 31:273-294.
25. Sharma, S. K., et al. 2003. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect. Genet. Evol. 3:183-188. (Pubitemid 37168746)
26. Vernon, A., W. Burman, D. Benator, A. Khan, and L. Bozeman. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843-1847. (Pubitemid 29251017)
27. World Health Organization. 2010. Global tuberculosis control: WHO report 2010. World Health Organization, Geneva, Switzerland.
28. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): global report on surveillance and response. Geneva, World Health Organization, Geneva, Switzerland.
29. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland.
30. Yeager, R. L., W. G. Munroe, and F. I. Dessau. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.